Navigation Links
Idenix Announces Removal of the Partial Clinical Hold on HCV Nucleotide Inhibitor, IDX184
Date:2/3/2012

CAMBRIDGE, Mass., Feb. 3, 2012 /PRNewswire/ -- Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that it has received notification from the U.S. Food and Drug Administration (FDA) that the partial clinical hold on IDX184 has been removed and that the Company's 12-week phase IIb study evaluating IDX184 in combination with pegylated interferon and ribavirin (PegIFN/RBV) may continue. IDX184, the Company's lead product candidate for the treatment of hepatitis C virus (HCV) infection is a pan-genotypic oral nucleotide polymerase inhibitor, and has demonstrated a high barrier to resistance in vitro and potent antiviral activity in both preclinical and clinical studies. Recently announced interim phase IIb data demonstrated favorable antiviral activity and no serious adverse events.

"After review of the interim safety and antiviral activity results from the IDX184 phase IIb clinical trial, the FDA removed the partial clinical hold and has allowed us to continue enrollment of this study," Ron Renaud, President and Chief Executive Officer of Idenix, commented. "Importantly, this allows us to expand the phase IIb program and evaluate IDX184 in interferon-free combination regimens with other direct-acting antivirals. We are working toward beginning all-oral combination trials as quickly as possible."

About IDX184 Phase IIb Study

In July 2011, Idenix initiated enrollment of treatment-naive genotype 1 HCV-infected patients into a randomized, double-blind, parallel group phase IIb clinical trial of IDX184. The study features two treatment arms, either 50 mg or 100 mg of IDX184 administered once-daily for 12 weeks, each arm in combination with PegIFN/RBV. Study objectives include safety and tolerability, and antiviral activity endpoi
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Idenix Pharmaceuticals Provides Update on Hepatitis C Pipeline at JP Morgan Healthcare Conference
2. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
3. Idenix Pharmaceuticals Reports First Quarter 2008 Financial Results
4. Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic
5. Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients
6. Idenix Pharmaceuticals Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
7. Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV
8. Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
9. Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2009 Financial Results
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Idenix Announces Data Presentations at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... May 22, 2015  In a sweeping analysis assessing ... T1D Exchange researchers conclude that there remains ... diabetes across all age groups, but especially for adolescents ... picture of diabetes treatment, underscoring the need to address ... that can help type 1 patients achieve optimal metabolic ...
(Date:5/21/2015)... 21, 2015 Research ... the addition of the "North American ... Digit Replacement, Elbow Replacement, Hip Replacement, Knee ... report to their offering. ,     (Logo: ... was valued at $4,470.9 million in 2014 ...
(Date:5/21/2015)... DUBLIN , May 21, 2015 /PRNewswire/ ... http://www.researchandmarkets.com/research/5x7nlz/arthroscopy ) has announced the addition of ... report to their offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... to analyze and size the world market ... players and identifies trends impacting the market ...
Breaking Medicine Technology:Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 2Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 3Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 4Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 5North American Joint Reconstruction Market 2015-2019 - Zimmer Holdings, DePuy Synthes Companies, Stryker, Biomet & Smith & Nephew Dominates the $4.4 Billion Market 2Analysing Arthroscopy Devices Markets Worldwide 2014-2020 2Analysing Arthroscopy Devices Markets Worldwide 2014-2020 3
... 7 NeuroVasx, Inc. announced,today the completion of a private ... of Minneapolis, MN and the Stephens Group of Little,Rock, AR. ... also announced completion of long term follow up on 20,patients ... which was completed in May. The company intends to announce ...
... Genomic Health,Inc. (Nasdaq: GHDX ) today announced ... DX(R) breast cancer test are scheduled to be ... Symposium, taking place,December 13-16, 2007. Oncotype DX is ... the likelihood of recurrence and the likelihood,of chemotherapy ...
Cached Medicine Technology:Genomic Health Announces Eight Oncotype DX(R) Studies to Be Presented at 30th Annual San Antonio Breast Cancer Symposium 2Genomic Health Announces Eight Oncotype DX(R) Studies to Be Presented at 30th Annual San Antonio Breast Cancer Symposium 3
(Date:5/22/2015)... 22, 2015 Following yesterday’s announcement that ... with US-based health brand Nature’s Way, Marc St-Onge has ... of Ascenta Skin is an integral part of the ... this opportunity to further develop Ascenta Skin into a ... Skin is a breakthrough, anti-aging skincare supplement featuring 6 ...
(Date:5/22/2015)... Family, friends, students, colleagues, mentors and fellow physicians ... D. Leffall, on Monday, May 18, with an 85th ... in the hospital’s Tower Auditorium. Leffall’s younger sister, 83-year-old ... to keep the secret. “I’d like to go in ... know something is up,” she said. , After more ...
(Date:5/22/2015)... Power Systems is proud to announce the sponsorship of Elite ... in his second year of racing in the professional division ... Department in Missoula, MT. He entered the triathlon scene in ... he has had 15 1st Place finishes. In his first ... all seven of his 2014 races, including two 2nd Place ...
(Date:5/22/2015)... May 22, 2015 Gateway Building Concepts ... renovations. The services the company specialize in include decks, ... basements, pool houses and much more. , The ... the owner of the company. It includes two geometrical ... design was thought out to be used with many ...
(Date:5/22/2015)... 22, 2015 DMG Productions announces the ... to broadcast on Friday, May 29, 2015 at 7:30 ... , In this episode Innovations will explore Interstate Restoration, ... business quickly through disaster recovery and restoration. , Additionally, ... works collaboratively to develop and deliver training and education ...
Breaking Medicine News(10 mins):Health News:Ascenta Skin President Announces Plans to Grow Brand 2Health News:Colleagues Surprise Dr. LaSalle Leffall with 85th Birthday Celebration 2Health News:New Episode of Innovations Airing Friday, May 29, 2015 Via Discovery Channel 2
... Internet access at home are much more likely to be ... research to be presented at the 105th Annual Meeting of ... social impacts of Internet use has been rather ambiguous about ... that Internet access has an important role to play in ...
... 2010) Once thought to be a problem primarily in,the developed ... disability,in poorer countries. Almost two-thirds of the 7.6 million cancer ... A paper to be published online in the Lancet ... now discard the notion that cancer is,a ,disease of the ...
... life adversity through poverty, social isolation or abuse in childhood ... disease later on, a leading expert on stress and disease ... can be traced back to childhood," Karen A. Matthews, PhD, ... Association. "Having some bad health habits in your 20s and ...
... of ovarian tissue cryopreservation and transplantation has lead to ... tumors, this method of fertility preservation may be unsafe ... study published online in Blood , the ... involves removing and freezing ovarian tissue before the patient ...
... patient,s blood or bone marrow that nourish blood vessels may ... cardiovascular disease than obtaining rare stem cells, according to research ... trials, doctors in several countries have tested the ability of ... heart attacks and peripheral artery disease, created by problems of ...
... , , , , , , ... AUDIO: ATS Past President, John. E. Heffner, M.D., discusses research linking acetaminophen use to increased asthma and eczema risk in adolescents. ... , , , , , , ... , , , , , , New evidence linking the use of acetaminophen to development ...
Cached Medicine News:Health News:Internet access at home increases the likelihood that adults will be in relationships 2Health News:Global health leaders advocate for expanding cancer care in developing countries 2Health News:Global health leaders advocate for expanding cancer care in developing countries 3Health News:Adversity in childhood can increase risk of cardiovascular disease in adulthood, research shows 2Health News:Adversity in childhood can increase risk of cardiovascular disease in adulthood, research shows 3Health News:Technique to preserve fertility in young women may be unsafe for patients with leukemia 2Health News:Technique to preserve fertility in young women may be unsafe for patients with leukemia 3Health News:Selected cells from blood or bone marrow may provide a route to healing blood vessels 2Health News:Selected cells from blood or bone marrow may provide a route to healing blood vessels 3Health News:Acetaminophen use in adolescents linked to doubled risk of asthma 2Health News:Acetaminophen use in adolescents linked to doubled risk of asthma 3Health News:Acetaminophen use in adolescents linked to doubled risk of asthma 4
Disposable Aluminum Satin Finish E/T Stylette, Adult 16, 25/box....
Hollow Copper Tube with Suction Port 16.5....
Surgical Stainless Steel Child Stylette....
Aluminum Stylette 16....
Medicine Products: